Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Vitamin E (alpha-tocopherol) has been studied for its potential role in inflammatory bowel disorders (IBD), such as Crohn’s disease and ulcerative colitis, primarily due to its antioxidant properties. Oxidative stress is believed to contribute to the pathogenesis of IBD, and Vitamin E, as a lipid-soluble antioxidant, can neutralize free radicals and reduce oxidative damage in tissues. Several preclinical studies using animal models of colitis have demonstrated that Vitamin E supplementation can attenuate inflammation, reduce mucosal damage, and improve histological scores. Small pilot studies in humans have also explored the use of topical (enema) and oral Vitamin E, with some reporting reductions in disease activity indices and improvements in clinical symptoms. However, these studies are limited in sample size, duration, and methodological rigor.

There is insufficient high-quality, large-scale clinical trial data to strongly support routine use of Vitamin E as a primary or adjunctive therapy for IBD. Major gastroenterology guidelines do not currently recommend Vitamin E supplementation for IBD management outside of correcting deficiencies. In summary, while there is a scientific rationale and preliminary evidence suggesting potential benefit, the overall quality and quantity of evidence are modest. The evidence is rated 2/5, reflecting possible but not well-established efficacy.

More about Vitamin E (alpha-tocopherol)
More about Inflammatory Bowel Disorders

Other ingredients used for Inflammatory Bowel Disorders

Other health conditions supported by Vitamin E (alpha-tocopherol)

Products containing Vitamin E (alpha-tocopherol)